Answer
The most frequently reported adverse reactions in Inbrija (inhaled levodopa) clinical studies were cough (15.6%), falls (8.7%), upper respiratory tract infection (5.8%), dyskinesia (5.7%) and discoloured sputum (2.8%).
Sources for this answer
- Inbrija 33mg inhalation powder, hard capsuleMerz Pharma UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 2Document updated
Sources checked